All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @elldicken on TikTok · 23s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @elldicken's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Oh, so he's not going

@elldicken's weight loss journey claims, fact-checked

Ellie | mama to 2 under 2

TikTok creator

75.5K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by slowing gastric emptying and reducing appetite through the incretin hormone system. Clinical trials show 15-22% weight loss depending on the specific medication and dose, but require ongoing treatment to maintain benefits.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @elldicken's weight loss journey claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@elldicken's weight loss journey claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@elldicken's weight loss journey claims, fact-checked" from Ellie | mama to 2 under 2. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by slowing gastric emptying and reducing appetite through the incretin hormone system.

The reason this review is not generic is the source wording and the canonical claim label "glp1 it s not been an easy journey but it s definitely been worth." In this clip, the useful excerpt is: "Oh, so he's not going" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

About 74% of people experience gastrointestinal side effects with GLP-1 medications, making the journey genuinely challenging for most users
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by slowing gastric emptying and reducing appetite through the incretin hormone system.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by slowing gastric emptying and reducing appetite through the incretin hormone system. Clinical trials show 15-22% weight loss depending on the specific medication and dose, but require ongoing treatment to maintain benefits.
  • Semaglutide produced 14.9% weight loss in the STEP 1 trial, while tirzepatide achieved up to 22.5% weight loss in SURMOUNT-1
  • About 74% of people experience gastrointestinal side effects with GLP-1 medications, making the journey genuinely challenging for most users

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Semaglutide produced 14.9% weight loss in the STEP 1 trial, while tirzepatide achieved up to 22.5% weight loss in SURMOUNT-1
  • About 74% of people experience gastrointestinal side effects with GLP-1 medications, making the journey genuinely challenging for most users
  • Weight loss benefits reverse quickly after stopping treatment, with participants regaining two-thirds of lost weight within one year
  • The SELECT trial showed 2.4mg semaglutide reduced major cardiovascular events by 20% in people with obesity
  • These medications require 16+ weeks to reach full therapeutic doses through careful escalation protocols
  • Monthly costs can exceed $1,000 without insurance coverage, creating significant access barriers
  • FDA monitoring requirements exist due to potential thyroid, gallbladder, and pancreatic risks observed in studies

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

@elldicken shares her weight loss transformation with phrases like "it's not been an easy journey but it's definitely been worth it." She uses hashtags suggesting a weight loss transformation and "glow up," though the video doesn't explicitly mention GLP-1 medications like semaglutide or tirzepatide.

The creator appears to be documenting her personal experience rather than making specific medical claims. She frames this as a difficult but rewarding process and encourages followers to see more of her journey.

Are weight loss transformations with GLP-1s actually difficult?

Yes, the journey is often challenging despite the medication's effectiveness. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% weight loss with 2.4mg semaglutide, but 74% of participants experienced gastrointestinal side effects.

Nausea affects about 44% of people starting semaglutide, with vomiting in 24% according to FDA prescribing information. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found that 15.3% of tirzepatide users discontinued treatment due to adverse events.

These medications require careful dose escalation over months. You start at 0.25mg semaglutide weekly, increasing every four weeks to reach the 2.4mg maintenance dose. That's a 16-week ramp-up period minimum.

Is significant weight loss actually "worth it" for health?

The clinical evidence suggests substantial health benefits from the weight loss these medications produce. The SELECT trial (Ryan et al., NEJM, 2023) found 2.4mg semaglutide reduced major cardiovascular events by 20% in people with obesity.

Weight loss of 15% or more can improve type 2 diabetes, sleep apnea, and blood pressure. The STEP 1 trial showed 68% of participants achieved at least 10% weight loss, with 32% losing 20% or more of their body weight.

However, calling any medical intervention "worth it" depends entirely on individual circumstances. Some people discontinue these medications due to side effects or cost, which can reach $1,000+ monthly without insurance coverage.

What's missing from this transformation narrative?

The video doesn't mention the ongoing nature of GLP-1 treatment or what happens when you stop. The STEP 1 trial extension showed participants regained about two-thirds of their lost weight within one year of discontinuing semaglutide.

There's also no discussion of the medication's mechanism. GLP-1 receptor agonists slow gastric emptying and reduce appetite through the incretin system. This isn't willpower; it's pharmaceutical appetite suppression.

The creator also doesn't address potential side effects beyond calling it "not easy." While she's not obligated to share medical details, viewers might benefit from knowing that gallbladder problems, pancreatitis, and severe gastroparesis, though rare, are documented risks requiring medical monitoring.

What should you actually know about GLP-1 weight loss?

These medications represent the most effective pharmaceutical weight loss treatments available. Tirzepatide showed 22.5% weight loss at the highest dose in SURMOUNT-1, rivaling bariatric surgery outcomes in some patients.

But they're not magic. Success requires ongoing treatment, lifestyle modifications, and medical supervision. The FDA requires Risk Evaluation and Mitigation Strategy (REMS) programs for some formulations due to thyroid C-cell tumor risks observed in animal studies.

Cost and access remain significant barriers. Insurance coverage varies widely, and ongoing shortages have affected availability. If you're considering these medications, work with healthcare providers familiar with GLP-1 prescribing protocols and monitoring requirements.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ellie | mama to 2 under 2 · TikTok creator

75.5K views on this video

It’s not been an easy journey but it’s definitely been worth it! Follow along to see more ❤️ #weightlosstransformation #fy #weightlossglowup #fyp

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide produced 14.9% weight loss in the step 1 trial,?

Semaglutide produced 14.9% weight loss in the STEP 1 trial, while tirzepatide achieved up to 22.5% weight loss in SURMOUNT-1

What does the video say about about 74% of people experience gastrointestinal side effects with glp-1?

About 74% of people experience gastrointestinal side effects with GLP-1 medications, making the journey genuinely challenging for most users

What does the video say about weight loss benefits reverse quickly after stopping treatment, with participants?

Weight loss benefits reverse quickly after stopping treatment, with participants regaining two-thirds of lost weight within one year

What does the video say about the select trial showed 2.4mg semaglutide reduced major cardiovascular events?

The SELECT trial showed 2.4mg semaglutide reduced major cardiovascular events by 20% in people with obesity

What does the video say about these medications require 16+ weeks to reach full therapeutic doses?

These medications require 16+ weeks to reach full therapeutic doses through careful escalation protocols

What does the video say about monthly costs can exceed $1,000 without insurance coverage, creating significant?

Monthly costs can exceed $1,000 without insurance coverage, creating significant access barriers

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ellie | mama to 2 under 2, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.